Reduced toxicity, attenuated immunogenicity and efficient mediation of human p53 gene expression in vivo by an adenovirus vector with deleted E1-E3 and inactivated E4 by GAL4-TATA promoter replacement

Gene Therapy

Volumn 6, Issue 3, 1999, Pages 393-402

  Ji, L ^a,b   Bouvet, M ^b   Price, R E ^b   Roth, J A ^b   Fang, B ^b  

^a Introgen Therapeutics Inc   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Adenovirus; E4 modification; Gene expression; Immunogenicity; p53; Toxicity

Indexed keywords

ALANINE AMINOTRANSFERASE; AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; GENE PRODUCT; VIRUS PROTEIN;

ADENOVIRUS; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BINDING SITE; CONTROLLED STUDY; EXPRESSION VECTOR; GENE EXPRESSION; IMMUNE RESPONSE; IMMUNOGENICITY; LIVER; LIVER TOXICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TATA BOX; TRANSGENE; TUMOR SUPPRESSOR GENE; VIRUS GENE; VIRUS REPLICATION; YEAST;

ADENOVIRIDAE; ADENOVIRUS E1 PROTEINS; ADENOVIRUS E2 PROTEINS; ADENOVIRUS E3 PROTEINS; ADENOVIRUS E4 PROTEINS; ADENOVIRUS EARLY PROTEINS; ANIMALS; CAPSID; CAPSID PROTEINS; GENE DELETION; GENE EXPRESSION; GENES, P53; GENETIC VECTORS; HUMANS; LIVER; MICE; MICE, INBRED C3H; MICE, INBRED C57BL; PROMOTER REGIONS (GENETICS); T-LYMPHOCYTES, CYTOTOXIC;

EID: 0033043390     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300825     Document Type: Article

References (38)

1. Chengalvala MV et al. Adenovirus vectors for gene expression. Curr Opin Biotechnol 1991; 2: 718-722.
2. Crystal RG. Transfer of genes to humans: early lessons and obstacles to success. Science 1995; 270: 404-410.
3. Gao GP, Yang Y and Wilson JM. Biology of adenovirus vectors with E1 and E4 deletions for liver-directed gene therapy. J Virol 1996; 70: 8934-8943.
4. Taneja SS, Pang S, Cohan P, Belldegrun A. Gene therapy: principles and potential. Cancer Surv 1995; 23: 247-266.
5. Trapnell BC, Gorziglia M. Gene therapy using adenoviral vectors. Curr Opin Biotechnol 1994; 5: 617-625.
6. Bridge E et al. Adenovirus early region 4 and viral DNA synthesis. Virology 1993; 193: 794-801.
7. Fang B, Koch P, Roth JA. Diminishing adenovirus gene expression and viral replication by promoter replacement. J Virol 1997; 71: 4798-4803.
8. Yang Y et al. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci USA 1994; 91: 4407-4411.
9. Engelhardt JF, Litzky L, Wilson JM. Prolonged transgene expression in cotton rat lung with recombinant adenoviruses defective in E2a. Hum Gene Ther 1994; 5: 1217-1229.
10. Lieber A, He CY, Kirillova I, Kay MA. Recombinant adenoviruses with large deletions generated by Cre-mediated excision exhibit different biological properties compared with first-generation vectors in vitro and in vivo. J Virol 1996; 70: 8944-8960.
11. Song WR, Kong HL, Traktman P, Crystal RG. Tytotoxic T lymphocyte responses to proteins encoded by heterologous transgenes transferred in vivo by adenoviral vectors. Hum Gene Ther 1997; 8: 1207-1217.
12. Yang Y, Ertl HC, Wilson JM. MHC class I-restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1-deleted recombinant adenoviruses. Immunity 1994; 1: 433-442.
13. Morral N et al. Immune responses to reporter proteins and high viral dose limit duration of expression with adenoviral vectors - comparison of E2a wild-type and E2a-deleted vectors. Hum Gene Ther 1997; 8: 1275-1286.
14. Tripathy SK, Black HB, Goldwasser E, Leiden JM. Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors. Nature Med 1996.; 2: 545-550.
15. Yang Y et al. Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytes in vivo. Gene Therapy 1996; 3: 137-144.
16. Yang YP, Haecker SE, Su Q, Wilson JM. Immunology of gene therapy with adenoviral vectors in mouse skeletal muscle. Hum Mol Genet 1996; 5: 1703-1712.
17. Armentano D et al. Effect of the e4 region on the persistence of transgene expression from adenovirus vectors. J Virol 1997; 71: 2408-2416.
18. Dedieu JF et al. Long-term gene delivery into the livers of immunocompetent mice with E1/E4-defective adenoviruses. J Virol 1997; 71: 4626-4637.
19. Falgout B, Ketner G. Adenovirus early region 4 is required for efficient virus particle assembly. J Virol 1987; 61: 3759-3768.
20. Halbert DN, Cutt JR, Shenk T. Adenovirus early region 4 encodes functions required for efficient DNA replication, late gene expression, and host cell shutoff. J Virol 1985; 56: 250-257.
21. Hemstrom C, Nordqvist K, Pettersson U, Virtanen A. Gene product of region E4 of adenovirus type 5 modulates accumulation of certain viral polypeptides. J Virol 1988; 62: 3258-3264.
22. Huang C, Deibel R. Nucleic acid hybridization for detection of cell culture-amplified adenovirus. J Clin Microbiol 1988; 26: 2652-2656.
23. Pilder S, Moore M, Logan J, Shenk T. The adenovirus E1B-55K transforming polypeptide modulates transport or cytoplasmic stabilization of viral and host cell mRNAs. Mol Cell Biol 1986; 6: 470-476.
24. Bondesson M et al. Adenovirus E4 open reading frame 4 protein autoregulates E4 transcription by inhibiting E1 A transactivation of the E4 promoter. J Virol 1996; 70: 3844-3851.
25. Kleinberger T, Shenk T. Adenovirus E4orf4 protein binds to protein phosphatase 2A, and the complex down-regulates E1A-enhanced junB transcription. J Virol 1993; 67: 7556-7560.
26. Dobner T, Horikoshi N, Rubenwolf S, Shenk T. Blockage by adenovirus E4orf6 of transcriptional activation by the p53 tumor suppressor. Science 1996; 272: 1470-1473.
27. Armentano D et al. Characterization of an adenovirus gene transfer vector containing an E4 deletion. Hum Gene Ther 1995; 6: 1343-1353.
28. Krougliak V, Graham FL. Development of cell lines capable of complementing E1, E4, and protein IX defective adenovirus type 5 mutants. Hum Gene Ther 1995; 6: 1575-1586.
29. Weinberg A et al. Enzyme linked immunosorbant assay: determination of anti-adenovirus antibodies in an infant population. Revista do Instituto de Medicina Tropical de Sao Paulo 1989; 31: 336-340.
30. Yeh P et al. Efficient dual transcomplementation of adenovirus E1 and E4 regions from a 293-derived cell line expressing a minimal E4 functional unit. J Virol 1996; 70: 559-565.
31. Shenk T, Jones N, Colby W, Fowlkes D. Functional analysis of adenovirus-5 host-range deletion mutants defective for transformation of rat embryo cells. Cold Spring Harbor Symp Quant Biol 1980; 44: 367-375.
32. Li H et al. Adenovirus-mediated wild-type p53 gene transfer and overexpression induces apoptosis of human glioma cells independent of endogenous p53 status. J Neuropathol Exp Neurol 1997; 56: 872-878.
33. Liu TJ et al. Apoptosis induction mediated by wild-type p53 adenoviral gene transfer in squamous cell carcinoma of the head and neck. Cancer Res 1995; 55: 3117-3122.
34. Brough DE et al. Activation of transgene expression by early region 4 is responsible for a high level of persistent transgene expression from adenovirus vectors in vivo. J Virol 1997; 71: 9206-9213.
35. Tyson CA, Story DL, Green CE. Traditionally used indicators in relation to pathologic lesions. In: Tyson CA, Sawhney DS (eds). Organ Function Tests in Toxicity Evaluation. Noyes Publications: Park Ridge, 1985, pp 23-88.
36. Barr D et al. Strain-related variations in adenovirally mediated transgene expression from mouse hepatocytes in vivo: comparisons between immunocompetent and immunodeficient inbred strains. Gene Therapy 1995; 2: 151-155.
37. Hardy S et al. Construction of adenovirus vectors through Crelox recombination. J Virol 1997; 71: 1842-1849.
38. Rittner K, Schultz H, Pavirani A, Mehtali M. Conditional repression of the E2 transcription unit in E1-E3-deleted adenovirus vectors is correlated with a strong reduction in viral DNA replication and late gene expression in vitro. J Virol 1997; 71: 3307-3311.